Dr. Lui Franciosi reports

HEALTH CANADA FINAL REVIEW NOTIFICATION RECEIVED FOR ACMPR APPLICATION

Pursuant to the news release announced Nov. 21, 2016, Sechelt Organic Marijuana Inc. has been notified by Health Canada that it has progressed into the final review stage of the access to cannabis for medical purposes regulations (ACMPR) application process. Veritas Pharma Inc. has been granted the exclusive option to acquire 100-per-cent ownership of Sechelt, subject to certain terms and conditions, including: obtaining an ACMPR/MMPR licence and the issuance of a permit by Health Canada for the building of a cannabis-growing facility.

Sechelt currently owns a secure commercial facility and land located in Sechelt, B.C., Canada, since July 4, 2014, and has had an application pending with Health Canada for a new ACMPR licence. Sechelt personnel includes an experienced grow master, who is currently a designated grower under current ACMPR licensing guidelines. Health Canada will now assess Sechelt's physical security plans to validate the information in its application.

"Sechelt sits with a minority of applicants who have successfully moved through the security clearance stage and into the final review stage," stated Veritas chief executive officer, Dr. Lui Franciosi. "We are excited by the prospect of Sechelt receiving its ACMPR licence in due course, which is a significant development for it, Veritas and Cannevert."

Veritas Pharma and Cannevert Therapeutics Ltd. have been actively preparing for their first clinical trials of select cannabis strains targeting pain some time this year. This scientific work forms the basis for Veritas's future branding and traction in the Canadian market, especially if Health Canada issues Sechelt a grower's licence. The company will be in a better position to produce special varieties of cannabis that have the ideal therapeutic characteristics. Upon Cannevert Therapeutics completing the clinical evidence and Sechelt obtaining a production licence, Veritas will be in a strong position to enter the United States with Marapharm Ventures Inc. as its key partner. Marapharm has significant ownership of Veritas.

Veritas would also like to announce that 400,000 stock options have been issued: 200,000 each to two consultants. The options will be vested immediately and have an exercise price of 47 cents. The options will expire, if unexercised, in one year from the date of issue. Further to the Jan. 12, 2017, bulletin of the issuance of warrants expiring on June 7, 2018, the company has paid 10 per cent or $50,000 in finders' fees to unrelated third parties.

About Sechelt Organic Marijuana Inc.

Sechelt was formed to become a producer of medical marijuana under the ACMPR licence. The products designed by Cannevert Therapeutics require the ability to grow specific strains of medical marijuana under ideal conditions. Sechelt provides Cannevert Therapeutics this ability.

About Veritas Pharma Inc.

Veritas Pharma is an emerging-stage pharmaceutical and intellectual property development company, which, through Cannevert Therapeutics (CTL), is advancing the science behind medical cannabis. It is the company's aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL's unique value proposition uses a low-cost research and development model to help drive shareholder value and speed to market. The company's commercial mission is to patent protect CTL's IP (cultivars and strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multibillion-dollar global markets.